| human | Q5 |
| P6178 | Dimensions author ID | 013063552625.08 |
| P496 | ORCID iD | 0000-0003-4024-0220 |
| P735 | given name | Bernhard | Q221978 |
| Bernhard | Q221978 | ||
| P106 | occupation | researcher | Q1650915 |
| Q91761628 | A comparison of very old patients admitted to intensive care unit after acute versus elective surgery or intervention |
| Q90116127 | Acidosis predicts mortality independently from hyperlactatemia in patients with sepsis |
| Q92056855 | Analysis of Novel Cardiovascular Biomarkers in Patients With Pulmonary Hypertension (PH) |
| Q93006643 | Anti-CD3 Antibody Treatment Reduces Scar Formation in a Rat Model of Myocardial Infarction |
| Q91660759 | Antithrombotic therapy for chronic coronary syndrome and atrial fibrillation: less might be more |
| Q92388929 | Antithrombotic therapy in atrial fibrillation: stop triple therapy and start optimizing dual therapy? |
| Q97411684 | Assessment of Cardiac Remodeling-A Chance for Novel Cardiac Biomarkers? |
| Q48165505 | Blood Urea Nitrogen (BUN) is independently associated with mortality in critically ill patients admitted to ICU. |
| Q57813214 | Blood parameter analysis after short term exposure to weightlessness in parabolic flight |
| Q61800796 | Carcinoid heart disease involving the left heart: a case report and biomarker analysis |
| Q101145169 | Cardiovascular health care and health literacy among immigrants in Europe: a review of challenges and opportunities during the COVID-19 pandemic |
| Q89861720 | Classic and Novel Biomarkers as Potential Predictors of Ventricular Arrhythmias and Sudden Cardiac Death |
| Q114029557 | Conundrum of Classifying Subtypes of Pulmonary Hypertension—Introducing a Novel Approach to Classify “Borderline” Patients in a Population with Severe Aortic Stenosis Undergoing TAVI |
| Q91667635 | Correction to: Antithrombotic therapy in atrial fibrillation: stop triple therapy and start optimizing dual therapy? |
| Q91291349 | Correction to: Transcatheter valve-in-valve implantation (VinV-TAVR) for failed surgical aortic bioprosthetic valves |
| Q64922720 | Disease-specific characteristics of vascular cell adhesion molecule-1 levels in patients with peripheral artery disease. |
| Q56967721 | Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease - A meta-analysis |
| Q95306805 | Dynamic Changes of Heart Failure Biomarkers in Response to Parabolic Flight |
| Q90670890 | Easy prognostic assessment of concomitant organ failure in critically ill patients undergoing mechanical ventilation |
| Q45789037 | Elevated plasma levels of interleukin-16 in patients with acute myocardial infarction |
| Q93190160 | Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls |
| Q56968412 | Extravascular lung water index and Halperin score to predict outcome in critically ill patients |
| Q104560061 | Failure of Lactate Clearance Predicts the Outcome of Critically Ill Septic Patients |
| Q39711310 | Global research trends in the medical therapy of pulmonary arterial hypertension 2000-2014. |
| Q47779505 | High peak PaO2 values associated with adverse outcome in patients treated with noninvasive ventilation for acute cardiogenic pulmonary edema and pneumonia |
| Q90451793 | Hypoglycemia but Not Hyperglycemia Is Associated with Mortality in Critically Ill Patients with Diabetes |
| Q92719025 | Impella®: an updated meta-analysis of available data and future outlook on applications in cardiogenic shock |
| Q47193481 | Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure. |
| Q57485016 | Insulin like growth factor binding protein 2 (IGFBP-2) for risk prediction in patients with severe aortic stenosis undergoing Transcatheter Aortic Valve Implantation (TAVI) |
| Q64080587 | Lactate Clearance Predicts Good Neurological Outcomes in Cardiac Arrest Patients Treated with Extracorporeal Cardiopulmonary Resuscitation |
| Q92544166 | Mechanical circulatory support with Impella versus intra-aortic balloon pump or medical treatment in cardiogenic shock-a critical appraisal of current data |
| Q88151791 | Model for End-Stage Liver Disease Excluding INR (MELD-XI) score is associated with hemodynamic impairment and predicts mortality in critically ill patients |
| Q36267363 | Model for End-stage Liver Disease excluding INR (MELD-XI) score in critically ill patients: Easily available and of prognostic relevance. |
| Q56966004 | Multi-biomarker analysis in patients after transcatheter aortic valve implantation (TAVI) |
| Q48165741 | Multibiomarker analysis in patients with acute myocardial infarction |
| Q90662820 | Novel Biomarkers in Patients with Chronic Kidney Disease: An Analysis of Patients Enrolled in the GCKD-Study |
| Q55098398 | Prime time for the sweet spot in timing of coronary invasive approach in patients with non-ST elevation myocardial infarction. |
| Q93382910 | Prognostic relevance of serum lactate kinetics in critically ill patients |
| Q91558739 | Real-world clinical experience with the percutaneous extracorporeal life support system: Results from the German Lifebridge® Registry |
| Q91870989 | Real-world extravascular lung water index measurements in critically ill patients : Pulse index continuous cardiac output measurements: time course analysis and association with clinical characteristics |
| Q97689489 | Red Blood Cell Peroxynitrite Causes Endothelial Dysfunction in Type 2 Diabetes Mellitus via Arginase |
| Q64065918 | Regenerative Cardiovascular Therapies: Stem Cells and Beyond |
| Q90566685 | Reply to the Letter to the Editor "Hypoglycemia and Mortality in Critically Ill Patients with Type 2 Diabetes" |
| Q88602710 | Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention |
| Q91108191 | Short-term dual antiplatelet therapy (DAPT) followed by P2Y12 monotherapy versus traditional DAPT in patients undergoing percutaneous coronary intervention: meta-analysis and viewpoint |
| Q38992231 | Stem Cell Therapy for Myocardial Infarction 2001-2013 Revisited |
| Q91666626 | Syndecan-1 Predicts Outcome in Patients with ST-Segment Elevation Infarction Independent from Infarct-related Myocardial Injury |
| Q96822349 | Testing House of God's Law VII: Was the Fat Man Right? |
| Q57297475 | Transcatheter aortic valve implantation without prior balloon valvuloplasty is associated with less pronounced markers of myocardial injury |
| Q91430276 | Transcatheter aortic valve replacement for pure aortic valve regurgitation: "on-label" versus "off-label" use of TAVR devices |
| Q56966000 | Transcatheter valve-in-valve implantation (VinV-TAVR) for failed surgical aortic bioprosthetic valves |
| Q90954435 | Trapping endothelin-1 to hunt down cardiovascular disease? |
| Q55159173 | Tricuspid Regurgitation - Medical Management and Evolving Interventional Concepts. |
| Q58598599 | Triple therapy: worth the risk? |
Search more.